Akebia is a high-risk nephrology turnaround where Vafseo must scale fast enough to outrun Auryxia’s collapse, cash burn, debt-like obligations, and dilution risk.
Overview
Akebia Therapeutics is a commercial-stage nephrology biotech focused on kidney disease, with revenue centered on Vafseo for dialysis-related anemia and Auryxia for hyperphosphatemia and iron deficiency anemia. Vafseo offers an oral alternative to injectable ESAs and is the company’s critical growth engine as Auryxia faces generic erosion. The company has meaningful commercial access through dialysis networks and international partnerships, but its future depends on rapid U.S. Vafseo adoption, successful observed-dosing integration, and its ability to manage cash burn, competition, and structured liabilities.